KR101387695B1 - The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus - Google Patents
The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus Download PDFInfo
- Publication number
- KR101387695B1 KR101387695B1 KR1020120049758A KR20120049758A KR101387695B1 KR 101387695 B1 KR101387695 B1 KR 101387695B1 KR 1020120049758 A KR1020120049758 A KR 1020120049758A KR 20120049758 A KR20120049758 A KR 20120049758A KR 101387695 B1 KR101387695 B1 KR 101387695B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- solid content
- audi
- root
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000003178 anti-diabetic effect Effects 0.000 title abstract description 14
- 239000003472 antidiabetic agent Substances 0.000 title abstract description 9
- 241000791271 Encephalartos senticosus Species 0.000 title 1
- 240000005166 Polygonatum biflorum Species 0.000 title 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 title 1
- 235000004506 Polygonatum multiflorum Nutrition 0.000 title 1
- 235000010575 Pueraria lobata Nutrition 0.000 title 1
- 244000046146 Pueraria lobata Species 0.000 title 1
- 239000007787 solid Substances 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229940072113 onion extract Drugs 0.000 claims description 8
- 235000013325 dietary fiber Nutrition 0.000 claims description 7
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 6
- 235000002789 Panax ginseng Nutrition 0.000 claims description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 6
- 241000018646 Pinus brutia Species 0.000 claims description 6
- 235000011613 Pinus brutia Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 244000298479 Cichorium intybus Species 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 240000001439 Opuntia Species 0.000 claims description 2
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 210000000287 oocyte Anatomy 0.000 claims description 2
- 240000001980 Cucurbita pepo Species 0.000 claims 1
- 235000009852 Cucurbita pepo Nutrition 0.000 claims 1
- 229940107588 barberry extract Drugs 0.000 claims 1
- 235000007882 dietary composition Nutrition 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 5
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 235000008708 Morus alba Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 241000723343 Cichorium Species 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 241000234282 Allium Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000376 effect on fatigue Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 자연 재료를 최적으로 선정 배합하여 우수한 항당뇨 효과를 얻도록 한 항당뇨 조성물에 관한 발명으로, 더욱 상세하게는 갈근, 둥굴레 줄기, 오디의 엑기스를 주성분으로 해서 배합한 항당뇨 조성물에 관한 것이다.
본 발명은 갈근 엑기스, 둥굴레 줄기 엑기스, 오디 엑기스를 주성분으로 한다.
이때 갈근 엑기스는 18~22중량%, 둥굴레 줄기 엑기스는 13~17중량%, 오디 엑기스는 13~17중량% 함유하는 것을 특징으로 한다.The present invention relates to an antidiabetic composition in which natural ingredients are optimally selected and blended to obtain an excellent antidiabetic effect. More particularly, the present invention relates to an antidiabetic composition comprising a root extract, a round stem, and an extract of Audi as a main component. will be.
The present invention has a root extract, a round stem extract, an Audi extract as a main component.
At this time, the root extract is 18 to 22% by weight, the round stalk extract is 13 to 17% by weight, Audi extract is characterized in that it contains 13 to 17% by weight.
Description
본 발명은 자연 재료를 최적으로 선정 배합하여 우수한 항당뇨 효과를 얻도록 한 항당뇨 조성물에 관한 발명으로, 더욱 상세하게는 갈근, 둥굴레 줄기, 오디의 엑기스를 주성분으로 해서 배합한 항당뇨 조성물에 관한 것이다.The present invention relates to an antidiabetic composition in which natural ingredients are optimally selected and blended to obtain an excellent antidiabetic effect. More particularly, the present invention relates to an antidiabetic composition comprising a root extract, a round stem, and an extract of Audi as a main component. will be.
본 발명에 따르면 자연 재료를 이용함으로써 약물 사용에 따른 부작용을 없애면서도 적절한 재료의 배합을 통해 우수한 항당뇨 효과를 거둘 수 있다.
According to the present invention it is possible to achieve an excellent anti-diabetic effect through the combination of the appropriate ingredients while eliminating the side effects of the use of natural materials.
당뇨병은 인슐린이 비정상적으로 분비되거나 분비되더라도 제대로 작용하지 못하여 포도당 대사가 원활하게 이루어지지 않는 질병이다. 인슐린은 포도당의 이용을 촉진하여 대사조절을 하기 때문에 이 작용이 부족해질 경우 포도당이 제대로 이용되지 못하고 신체세포는 에너지 부족상태에 빠지게 된다. 혈액 중의 포도당은 이용되지 않고 잔류하여 당뇨병의 특징인 고혈당이 된다.Diabetes is a disease in which glucose metabolism does not work well even if insulin is secreted or secreted abnormally. Insulin promotes the use of glucose to regulate metabolism, so when this action is insufficient, glucose is not properly used and body cells are in a state of energy deprivation. Glucose in the blood remains unused and becomes hyperglycemic, a hallmark of diabetes.
당뇨병은 서구의 식생활과 비슷해지면서 생긴 비만, 고혈압, 심장병, 동맥경화 같은 성인병 중 하나이다. 성인 인구의 10%를 차지할 만큼 심각한 문제로 대두되고 있고, 그 합병증 또한 심각하여 당뇨성 신경장애, 망막증, 동맥경화증 등을 유발하여 뇌졸중이나 심장병을 부른다.Diabetes is one of the adult diseases such as obesity, high blood pressure, heart disease, and arteriosclerosis caused by a similar diet to the Western diet. It is a serious problem that accounts for 10% of the adult population, and its complications are also serious, causing diabetic neuropathy, retinopathy, and atherosclerosis, leading to stroke or heart disease.
당뇨병에는 두 가지 유형이 있다. 제1형 당뇨병은 인슐린 의존형으로 유전적 요인에 의해 β세포가 파괴되는 것으로 알려져 있다. 인슐린을 전혀 생산하지 못하는 게 원인이 되어 발생한다.There are two types of diabetes. Type 1 diabetes mellitus is insulin dependent, and β cells are known to be destroyed by genetic factors. It is caused by not producing any insulin at all.
제2형 당뇨병은 인슐린 비의존형 또는 성인형 당뇨병이라고도 한다. 비만, 스트레스, 식생활 잘못, 또는 인슐린과 길항(拮抗)하는 약물 등에 의해 발병하며 전체 당뇨병 환자의 95% 이상이 제2형 당뇨병에 속한다.
Type 2 diabetes is also referred to as insulin independent or adult diabetes. It is caused by obesity, stress, poor diet, or drugs that antagonize insulin, and more than 95% of all diabetics belong to type 2 diabetes.
당뇨병의 원인은 아직까지 정확히 밝혀지지 않았으며 유전, 비만, 바이러스 감염, 스트레스, 약물남용, 운동부족 등과 관련이 있는 것으로 알려져 있다. 정확한 원인을 밝히지 못했듯이 완치가 어려운 질병으로 여겨지며 치료 또한 쉽지 않다.The cause of diabetes is not known yet, and it is known to be related to heredity, obesity, viral infections, stress, drug abuse, and lack of exercise. As the exact cause is not known, it is considered difficult to cure and difficult to treat.
서양의학 치료법의 경우, 경구혈당강하제나 인슐린 주사 등의 약물요법에 의한 혈당 조절관리에 치중하면서 규칙적인 식사와 운동으로 당뇨를 조절하는데 실제 당사자는 식이조절, 규칙적 운동, 주사제 투입 등의 치료법이 쉽지 않다. 또한 시중에서 판매하는 약물의 대부분은 끊임없이 복용해야 하므로, 약물의 장기 투여로 말미암아 나타나는 부작용을 감수해야 한다.
In Western medicine, diabetes is controlled by regular diet and exercise while focusing on glycemic control by oral hypoglycemic drugs or insulin injections. not. Also, most of the drugs on the market must be taken on an ongoing basis, so bear the side effects of long-term administration of the drug.
본 발명은 상기와 같은 배경에서 안출된 것으로, 자연 재료를 이용하여 약물 사용에 따른 부작용을 없애면서도 그 배합을 적절히 하여 우수한 항당뇨 효과를 보이는 조성물을 제공하는 데 그 목적이 있다.The present invention has been made in the background as described above, the object of the present invention is to provide a composition exhibiting excellent anti-diabetic effect by appropriately blending while eliminating side effects due to drug use using natural materials.
본 발명의 조성물은 액상 형태이므로 환자가 섭취하기가 매우 용이하며 이를 섭취할 경우 혈중 당 함량이 지속적으로 떨어지게 된다.
Since the composition of the present invention is in liquid form, it is very easy for the patient to ingest, and when ingested, the blood sugar content continuously decreases.
상기와 같은 본 발명은 갈근 엑기스, 둥굴레 줄기 엑기스, 오디 엑기스를 주성분으로 하는 항당뇨 조성물인 것을 특징으로 한다.The present invention as described above is characterized in that the anti-diabetic composition, the main component of the root extract, the round stem extract, the Audi extract.
더 구체적으로 본 발명의 항당뇨 조성물은 갈근 엑기스 18~22중량%, 둥굴레 줄기 엑기스 13~17중량%, 오디 엑기스는 13~17중량%를 함유하는 것을 특징으로 한다.More specifically, the anti-diabetic composition of the present invention is characterized in that it contains 18-22% by weight of the root extract, 13-17% by weight of the oleander stem extract, and 13-17% by weight of the Audi extract.
더 구체적으로 갈근 엑기스 20중량%, 둥굴레 줄기 엑기스 15중량%, 오디 엑기스 15중량%, 양파 엑기스 15중량%, 가시오가피 엑기스 15중량%, 솔잎 엑기스 13.5중량%, 비타민 C 2중량%, 비타민 E 2중량%, 홍삼 엑기스 2중량%, 치커리 식이섬유 0.5중량%로 이루어지는 것을 특징으로 한다.More specifically, 20% by weight of the root extract, 15% by weight of the round stalk extract, 15% by weight of the Audi extract, 15% by weight of the onion extract, 15% by weight of the skin extract, pine needle extract 13.5%, vitamin C 2% by weight, vitamin E 2% %, Red ginseng extract 2% by weight, chicory dietary fiber is characterized by consisting of 0.5% by weight.
이때 갈근 엑기스의 고형분은 15~20중량%, 둥굴레 줄기 엑기스의 고형분은 20~25중량%, 오디 엑기스의 고형분은 20~25중량%, 양파 엑기스의 고형분은 20~25중량%, 가시오가피 엑기스의 고형분은 20~25중량%, 솔잎 엑기스의 고형분은 20~25중량%, 홍삼 엑기스의 고형분은 60~65중량%인 것을 특징으로 한다.At this time, the solid content of the root extract is 15-20% by weight, the solid content of the round stalk extract is 20-25% by weight, the solid content of the Audi extract is 20-25% by weight, the solid content of the onion extract is 20-25% by weight, the solid content of the skin extract Silver is 20-25% by weight, solid content of pine needle extract is 20-25% by weight, solid content of red ginseng extract is characterized in that 60-65% by weight.
또한 이때 갈근 엑기스, 둥굴레 줄기 엑기스, 오디 엑기스, 양파 엑기스 및 가시오가피 엑기스는, (1) 각 원료를 선별 정선하여 추출기에 넣고 물을 가하여 80~90에서 추출한 후, (2) 그 추출물을 감압농축기에서 농축한 다음, (3) 물로 고형분의 양을 정해진 수치범위로 조절하여 준비한 것임을 특징으로 한다.
Also, at this time, the root extract, round stalk extract, audi extract, onion extract and thorny oocyte extract, (1) select each raw material, select it, put it in an extractor, add water and extract it at 80 ~ 90, and then (2) extract the extract in a reduced pressure concentrator. After concentration, (3) characterized in that prepared by adjusting the amount of solids to a predetermined numerical range with water.
본 발명에서 사용되는 주원료들에 대해 설명한다.The main raw materials used in the present invention will be described.
갈근은 석류가 갖는 식물성 에스트로겐이 625배나 많은 것처럼 장점이 많은 천연원료이다. 식이섬유질이 풍부하고 사포닌 성분 또한 많이 함유되어 있어서 당뇨, 고혈압에 좋다. 갈근은 땅속에서 물 및 영양분을 빨아들여 굵은 몸속에 저장한다. 섭취하게 되면 사람의 몸속에서 수분 및 영양분을 조절하여 피로회복(간 기능 회복), 부종, 황달 등에 큰 효과를 볼 수 있다.Brown root is a natural ingredient with many advantages, such as 625 times more phytoestrogens in pomegranates. It is rich in dietary fiber and contains a lot of saponin, which is good for diabetes and high blood pressure. The reed sucks water and nutrients from the ground and stores them in a thick body. When ingested, the body's body can control moisture and nutrients, which can have a great effect on fatigue (recovering liver function), edema, jaundice, etc.
둥굴레 줄기는 약리적으로 혈압과 심장, 혈당에 주로 작용한다. 둥굴레 줄기는 허약 체질, 폐결핵, 마른기침, 갈증에 좋으며, 심장을 튼튼하게 하므로 심장쇠약, 협심증 등 심장 질환이 있는 사람에게도 좋다. 또 식은땀과 원인 모르게 얼굴로 열이 오르면서 가슴이 답답하거나 수족에 열감이 있어 갑갑하게 느껴지는 사람, 노화방지에도 더불어 좋은 천연식품이다.It is pharmacologically acting mainly on blood pressure, heart and blood sugar. Duckle stem is good for weak constitution, pulmonary tuberculosis, dry cough, thirst, and strengthens the heart, so it is good for people with heart disease, such as heart failure, angina pectoris. It is also a good natural food for people who feel frustrated due to cold sweating and fever with their face unknowingly causing the chest to feel stuffy or have limbs in their hands and feet.
양파는 혈액 속의 불필요한 지방과 콜레스테롤을 녹여 동맥경화와 고지혈증을 예방하며, 고혈압 예방과 치료에도 탁월하고, 혈당을 저하시키는 작용과 인슐린의 분비를 촉진시켜 당뇨병 예방 및 치료에 좋은 재료이다. 지방의 함량이 적고 채소로서는 단백질이 많은 편이라 고른 영양섭취에 필요하다. 또한 칼슘과 철분의 함량이 많아 강장효과를 돋우는 역할을 한다. 혈액을 정화하기 때문에 피부미용에도 좋고 잔주름을 예방한다.Onion dissolves unnecessary fat and cholesterol in the blood to prevent atherosclerosis and hyperlipidemia. It is also excellent for preventing and treating hypertension, and it is a good material for preventing and treating diabetes by promoting the action of lowering blood sugar and promoting insulin secretion. It is low in fat and contains a lot of protein as a vegetable, so it is necessary for even nutrition. In addition, it has a high content of calcium and iron, which plays a role in enhancing the tonic effect. It cleanses the blood, so it is good for skin care and prevents fine lines.
가시오가피는 생리학적으로 전반적인 기능 증대, 대사촉진작용, 동맥혈압의 정상화, 항염작용, 항암작용, 항당뇨작용, 해독작용, 환경변화에 대한 적응능력 향상 등의 약리 효능을 갖고 있다.Psoriasis has pharmacological effects such as physiological improvement of overall function, metabolic promoting action, normalization of arterial blood pressure, anti-inflammatory action, anticancer action, antidiabetic action, detoxification action and improvement of adaptation ability to environmental changes.
오디는 신체의 모든 기능들을 전체적으로 향상하고 눈과 귀를 맑게 만들어 주는 효능이 있다. 오디는 유리당 성분 조성 및 혈당저하 성분을 함유하고 있다. 혈당을 떨어뜨려 주는 성분으로 알려진 디엔제이(DNJ)를 뽕잎과 같은 정도로 함유하고 있을 뿐만 아니라 오디 속에 존재하는 당분은 과당과 포도당만으로 조성되어 있어 설탕을 배제시켜야 하는 당뇨환자식 등에 매우 유용하다. 또한 고혈압 억제물질 루틴을 높게 함유하고 있으며 불포화지방산 함량이 87%로 매우 높다. 동의보감도 탕액편에서 "까만 오디는 뽕나무의 정령이 모여 있는 것이며, 당뇨병에 좋고 오장에 이로우며, 오래 먹으면 배고픔을 잊게 해준다"고 한다.
Audi has the effect of improving all the functions of the body as a whole and clearing eyes and ears. Audi contains a free sugar component composition and a hypoglycemic component. DJJ, known to lower blood sugar, contains mulberry leaves as much as mulberry leaves, and the sugar present in Audi is composed of fructose and glucose, which is very useful for diabetic patients who need to exclude sugar. In addition, it contains a high level of hypertension inhibitor routines and a very high unsaturated fatty acid content of 87%. Dongbogam is also in the liquid juice "Black Audi is the soul of mulberry trees are gathered, good for diabetes, good for the five chapters, long eating will make you forget hunger."
본 발명은 위와 같은 재료들을 전에 없던 방식과 함량으로 결합한 점에 특징이 있다.
The present invention is characterized by combining the above materials in a manner and in a content that has not been provided before.
본 발명에 따르면 자연 재료를 이용함으로써 약물 사용에 따른 부작용을 없애면서도 적절한 재료의 배합을 통해 우수한 항당뇨 효과를 거둘 수 있다.According to the present invention it is possible to achieve an excellent anti-diabetic effect through the combination of the appropriate ingredients while eliminating the side effects of the use of natural materials.
또한 본 발명의 조성물은 액상 형태이므로 환자가 섭취하기가 매우 용이하다.
In addition, since the composition of the present invention is in liquid form, it is very easy for the patient to consume.
이하 본 발명을 실시예와 함께 상세히 설명한다.
Hereinafter, the present invention will be described in detail with reference to examples.
1. 구성물질 및 함량1. Composition and Content
- 갈근 엑기스(고형분 15%) 20중량%-20% by weight of root extract (solid 15%)
- 둥굴레 줄기 엑기스(고형분 20%) 15중량%-15% by weight of round stalk extract (20% solids)
- 오디추출물(고형분 20%) 15중량%-15% by weight of Audi extract (solid content 20%)
- 양파 엑기스(고형분 20%) 15중량%-15% by weight of onion extract (20% solids)
- 가시오가피 엑기스(고형분 20%) 15중량%-15% by weight of Shigagapi Extract (20% solids)
- 솔잎 엑기스(고형분 20%) 13.5중량%-Pine needle extract (20% solids) 13.5% by weight
- 비타민 C 2중량%2% by weight of vitamin C
- 비타민 E 2중량%2% by weight of vitamin E
- 홍삼 엑기스(고형분 60%) 2중량%-Red ginseng extract (60% solids) 2% by weight
- 치커리 식이섬유 0.5중량%
-0.5% by weight of chicory dietary fiber
2. 2.
항당뇨Anti-diabetic
조성물의 제조 Preparation of composition
원료 갈근을 선별 정선하여 추출기에 넣고 용매(물)를 가하여 90에서 6~7시간씩 3회 반복 추출하였다. 이 추출액을 250mesh 여과기에서 가압식으로 여과하고 감압 농축기에 옮겨 400~700 mmHg, 50~80에서 농축하였다(이때 고형분은 대략 60% 정도였다). 이 농축액에 물을 넣어 고형분 15%로 조정하였다.The raw roots were screened and selected and placed in an extractor, followed by extracting three times at 90 to 6 to 7 hours by adding a solvent (water). The extract was filtered under pressure in a 250mesh filter, transferred to a vacuum concentrator, and concentrated at 400-700 mmHg, 50-80 (at which the solid content was about 60%). Water was added to this concentrate, and the solid content was adjusted to 15%.
둥굴레 줄기, 양파, 가시오가피, 오디, 솔잎, 홍삼의 엑기스도 같은 과정을 통해 위에 같은 방식으로 준비하였다.Extracts of stalks, onions, prickly pears, mulberry, pine needles, and red ginseng were prepared in the same manner.
그다음 위 각 엑기스와 치커리 식이섬유 및 비타민 C, E를 배합하였다.Next, each extract was combined with chicory fiber and vitamins C and E.
치커리 식이섬유는 일반적으로 상품화하여 분말 형태로 판매하는 것을 사용하여도 무방하며 본 실험에서도 그와 같이 하였다.
Chicory dietary fiber is generally commercialized and sold in powder form.
3. 실험3. Experiment
가. 실험동물 : 실험용 수컷 쥐(200±10g)
end. Experimental animal : Experimental male rat (200 ± 10g)
나. 당뇨 유발용 시약I. Diabetic Reagents
당뇨유발 시약 Streptozotocin(sigma S-0130)을 이용하여 실험동물(rat 수컷 체중 200±10g)의 복강에 주사하고 일주일 후 쥐(rat)의 안구에서 채혈한 다음, 혈당측정기를 이용하여 혈당 측정 후, 혈당이 고혈당으로 높아진 쥐를 선발하여 실험동물로 이용하였다.
After injection into the abdominal cavity of the experimental animal (rat male body weight 200 ± 10g) using the diabetes-induced reagent Streptozotocin (sigma S-0130), blood was collected from rat eye one week later, and then blood glucose measurement was performed using a blood glucose meter. Rats whose blood glucose was elevated to hyperglycemia were selected and used as experimental animals.
다. 처리방법All. Processing method
① 당뇨 유발된 쥐를 선발하여 한 처리구에 20수씩을 배치하였다.① Diabetes-induced rats were selected and placed 20 animals in one treatment group.
② 본 발명에 따른 혼합 조성물을 급여하지 않는 대조군과, 3ml/1일/수, 2.5ml/1일/수, 2.0ml/1일/수 등의 급여군으로 나누어 총 4처리구로 하였다. 투여 방법은 존데(sonde)를 이용하여 매일 경구 투여하는 것으로 하였다.② The control composition was not fed the mixed composition according to the present invention and 3ml / 1 day / water, 2.5ml / 1 day / water, 2.0ml / 1 day / water and divided into salary groups such as 4 treatment groups. The administration method was oral administration daily using sonde.
③ 실험기간은 4주일 간 실시하였으며 실험 개시 전 혈당측정을 비롯하여 일주일 간격으로 총 5회에 걸쳐 경구채혈 하여 혈당을 측정하였다.
③ The experiment period was conducted for 4 weeks. Blood glucose was measured by oral blood collection 5 times a week apart from blood glucose measurement before the start of the experiment.
4. 실험 결과4. Experimental Results
가. 체중 측정 결과end. Weight measurement results
실험기간 동안 일주일 간격으로 체중을 측정한 결과 혼합물 투입군은 처음 혈당치가 높았을 때는 체중이 감소하는 결과를 보였으나 3주일이 경과한 후 거의 정상적으로 증가하는 현상을 보였다. As a result of measuring the body weight at weekly interval during the experiment, the mixture group showed a weight loss when the blood sugar level was high for the first time, but increased almost normally after 3 weeks.
반면 대조군(본 발명에 따른 혼합물을 투여하지 않은 쥐)의 경우는 체중이 4주 동안 회복의 기미가 보이지 않았다.
On the other hand, the control group (the rat not administered the mixture according to the present invention) showed no signs of recovery for 4 weeks.
<표 1. 쥐의 4주간 체중 변화><Table 1.Weight Changes in Rats>
<그래프 1. 쥐의 4주간 체중 변화>Graph 1.Weight Changes in Rats>
나. 혈당 측정 결과I. Blood sugar measurement result
혼합물 투여를 한 경우는 2주일 만에 정상수치의 혈당을 얻을 수 있었다. 그래서 3주간만 투여하고 정상수치가 계속 지속되는가를 알아보기 위하여 1주일 동안은 투여하지 않았다.When the mixture was administered, normal blood glucose levels were obtained within two weeks. Therefore, only three weeks of administration and did not administer for a week to see if the normal value continues.
① 미투여군 : 최초 434.90mg/에서 2주일이 지난 후에는 241.10mg/로 회복의 가능성을 보였으나 4주일 경과 후에는 396.44mg/로 악화되었다.(1) Unadministered group: At 2 weeks after the first 434.90mg /, the patient recovered to 241.10mg /, but deteriorated to 396.44mg / after 4 weeks.
② 2.0ml 투여군 : 최초 293.7mg/에서 2주일이 지난 후에는 132.80mg/로 거의 정상적인 회복을 보였으나 4주일 경과 후에는 189.00mg/ 다시 높아지는 경향 보였다.② 2.0ml group: At 2 weeks after the first 293.7mg / 132.80mg / was almost normal recovery, but after 4 weeks 189.00mg / tended to increase again.
③ 2.5ml 투여군 : 최초 263mg/에서 2주일이 지난 후에는 94.8mg/로 완전히 정상으로 측정되었다.③ 2.5ml administration group: After 2 weeks at the first 263mg / 94.8mg / was completely normal.
④ 3.0ml 투여군 : 최초 333.2mg/에서 2주일이 지난 후에는 100.80mg/로 완전히 정상적인 결과를 보였다.
④ 3.0ml group: The first 333.2mg / 2 weeks after 100.80mg / showed a completely normal result.
<표 2. 4주간의 혈당 측정 결과>Table 2. Blood glucose measurement results for 4 weeks
<그래프 2. 4주간의 혈당 측정 그래프><Graph 2. Blood glucose measurement graph for 4 weeks>
<표 3. 혼합물 미투여 쥐와 투여 쥐와의 혈당 비교표>Table 3. Comparison of Blood Glucose Level between Unmixed and Untreated Mice
5. 실험결과에 대한 평가5. Evaluation of Experimental Results
가. 체중 측정 결과의 end. Of weight measurement results
유의미성Significance
당뇨병의 대표적 증상은 다음, 다뇨, 다식이다. 혈액 속의 포도당 농도가 높아지면 혈액에 있는 당분이 소변을 통해서 배설된다. 이때 체내의 수분도 함께 빠져 나가기 때문에 소변의 양과 횟수가 많아지는 것이다. 또 이로 인해 탈수 현상으로 물을 많이 마시게 된다. 사람에 따라 차이는 있지만 하루에 3~4리터 또는 그 이상을 마시는 게 보통이다. 그리고 공복감이 심해져서 식사량이 는다. 이처럼 다식을 하지만 체중은 오히려 빠져서, 심한 경우에는 2~3개월 사이에 10kg까지 빠지는 경우도 있다. 수분은 배출되고 다식을 해도 체중은 오히려 감소하고 체내에 필요한 영양분을 제대로 섭취하지 못하며, 그래서 또 쉽게 피로를 느끼고 무기력감을 느낀다.Representative symptoms of diabetes are the following: polyuria, polyps. As glucose levels in the blood increase, sugar in the blood is excreted in the urine. At this time, the amount of water and the number of urine increases because the body also escapes moisture. In addition, due to the dehydration phenomenon to drink a lot of water. Depending on the person, it is common to drink three to four liters or more per day. And the feeling of fasting worsens, the amount of meals is high. Like this, but the weight is rather missing, in severe cases may fall up to 10kg in 2-3 months. When water is released and you have a lot of food, you lose weight and do not get the nutrients you need, so you can easily feel tired and lethargic.
위 실험에서는 혼합 조성물을 음용했을 때 3주일이 경과한 후 체중이 거의 정상적으로 증가했음을 볼 수 있다. 체중 회복 및 증가의 유의미성은 2.0ml, 2.5ml, 3.0ml 투여군이 모두 갖는다. 실험 전 체중을 정상회복하거나 실험 전보다 증가하는 보다 큰 개선 군은 2.5ml, 3ml 군이라 할 수 있다.In the above experiments, when the mixed composition was drunk after three weeks, the weight can be seen to increase almost normally. Significance of weight recovery and gain was all the 2.0ml, 2.5ml, 3.0ml administration group. The larger improvement group that normalized the weight before the experiment or increased before the experiment could be referred to as the 2.5ml and 3ml groups.
이러한 효과는 혈당치가 낮아진 것과 더불어 중요한 회복의 징후라 볼 수 있다.
These effects, along with lowered blood sugar levels, are important signs of recovery.
나. 혈당 측정 결과I. Blood sugar measurement result
위에 살핀 것처럼 발명자는 당뇨 유발된 쥐들에 발명 혼합물을 투여하지 않거나 투여량을 조절해서 혼합물의 효능 효과를 비교 체크하였다.As shown above, the inventors compared the efficacy effects of the mixtures by not administering the invention mixture or adjusting the dose to the diabetic rats.
그 결과 혼합물을 투여한 쥐들은 대체로 정상적인 혈당치를 보였으나, 투여하지 않은 쥐들은 4주가 지나도 회복의 기미가 없었다. 따라서 본 발명에 따른 추출물은 당뇨에 우수한 효과를 가짐을 알 수 있다.As a result, the rats treated with the mixture generally showed normal blood glucose levels, but the rats without administration showed no signs of recovery after 4 weeks. Therefore, it can be seen that the extract according to the present invention has an excellent effect on diabetes.
한편 혈당 수치 저하의 유의미성은 2.0ml, 2.5ml, 3.0ml 투여군이 모두 갖는다. 실험 전 혈당수치로 정상회복하거나 실험 전보다 수치 이하로서, 보다 큰 개선을 보인 군은 2.5ml, 3ml 군이라 할 수 있다. 상기 결과로 보면, 체중 200±10g의 동물실험에 1일 2.5ml와 3.0ml의 투여가 최상의 효과를 나타냄을 알 수 있는바, 본 발명의 실시 시 제품의 1일 섭취용량에 대한 계산의 토대로 활용할 수 있다.On the other hand, the significance of lowering blood glucose level was all 2.0ml, 2.5ml, 3.0ml administration group. Before the experiment, the blood sugar level returned to normal or below the level before the experiment, and the group showing a greater improvement may be referred to as a 2.5ml, 3ml group. From the above results, it can be seen that the daily administration of 2.5ml and 3.0ml showed the best effect in the animal experiment of body weight 200 ± 10g, and was utilized as a basis for calculation of the daily intake of the product in the practice of the present invention. Can be.
또한 위 실험결과로부터 일정량 이상을 투여할 경우 유의미한 효과를 거둘 수 있음을 알 수 있다.In addition, it can be seen from the above experimental results that a significant amount can be achieved if a certain amount or more is administered.
Claims (5)
갈근 엑기스는 18~22중량%, 둥굴레 줄기 엑기스는 13~17중량%, 오디 엑기스는 13~17중량% 함유하는 것을 특징으로 하는 당뇨 예방 및 개선용 식품 조성물.The method of claim 1,
The root extract is 18-22% by weight, the round stalk extract is 13-17% by weight, the Audi extract is 13 to 17% by weight of the food composition for preventing and improving diabetes.
갈근 엑기스 20중량%, 둥굴레 줄기 엑기스 15중량%, 오디 엑기스 15중량%, 양파 엑기스 15중량%, 가시오가피 엑기스 15중량%, 솔잎 엑기스 13.5중량%, 비타민 C 2중량%, 비타민 E 2중량%, 홍삼 엑기스 2중량%, 치커리 식이섬유 0.5중량%로 이루어지는 것을 특징으로 하는 당뇨 예방 및 개선용 식품 조성물.3. The method of claim 2,
20% by weight of brown root extract, 15% by weight of round stalk extract, 15% by weight of audi extract, 15% by weight of onion extract, 15% by weight of barberry extract, 13.5% by weight of pine needles extract, 2% by weight of vitamin C, 2% by weight of vitamin E, red ginseng Extract 2% by weight, dietary fiber composition for preventing and improving diabetes, characterized in that consisting of 0.5% by weight of chicory dietary fiber.
갈근 엑기스의 고형분은 15~20중량%, 둥굴레 줄기 엑기스의 고형분은 20~25중량%, 오디 엑기스의 고형분은 20~25중량%, 양파 엑기스의 고형분은 20~25중량%, 가시오가피 엑기스의 고형분은 20~25중량%, 솔잎 엑기스의 고형분은 20~25중량%, 홍삼 엑기스의 고형분은 60~65중량%인 것을 특징으로 하는 당뇨 예방 및 개선용 식품 조성물.The method of claim 3,
The solid content of the root extract is 15-20% by weight, the solid content of the round stalk extract is 20-25% by weight, the solid content of the Audi extract is 20-25% by weight, the solid content of the onion extract is 20-25% by weight, and the solid content of the thorny skin extract is 20-25% by weight, solid content of pine needle extract is 20-25% by weight, solid content of red ginseng extract is 60-65% by weight, the food composition for preventing and improving diabetes.
갈근 엑기스, 둥굴레 줄기 엑기스, 오디 엑기스, 양파 엑기스 및 가시오가피 엑기스는, (1) 각 원료를 선별 정선하여 추출기에 넣고 물을 가하여 80~90℃에서 추출한 후, (2) 그 추출물을 감압농축기에서 농축한 다음, (3) 물로 고형분의 양을 정해진 수치범위로 조절하여 준비한 것임을 특징으로 하는 당뇨 예방 및 개선용 식품 조성물.5. The method of claim 4,
Brown root extract, round stalk extract, audi extract, onion extract, and thorny oocyte extract, (1) select each raw material, select it, place it in an extractor, add water and extract it at 80 ~ 90 ℃, and then (2) concentrate the extract in a reduced pressure concentrator. Then, (3) the food composition for preventing and improving diabetes, characterized in that prepared by adjusting the amount of solids to a predetermined numerical range with water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120049758A KR101387695B1 (en) | 2012-05-10 | 2012-05-10 | The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120049758A KR101387695B1 (en) | 2012-05-10 | 2012-05-10 | The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130126022A KR20130126022A (en) | 2013-11-20 |
KR101387695B1 true KR101387695B1 (en) | 2014-04-21 |
Family
ID=49854202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120049758A KR101387695B1 (en) | 2012-05-10 | 2012-05-10 | The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101387695B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104904942A (en) * | 2015-06-05 | 2015-09-16 | 王德富 | Blood glucose reducing tea and preparation method thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102183687B1 (en) | 2017-10-31 | 2020-11-27 | 안국건강 주식회사 | Extract of Polygonatum odoratum for preventing non-alcoholic fatty liver |
CN107875328A (en) * | 2017-11-29 | 2018-04-06 | 张天文 | A kind of integration of drinking and medicinal herbs electuary of the multiple compensation of remaining β cells |
CN108308242A (en) * | 2018-05-09 | 2018-07-24 | 河南中医药大学 | A kind of Pueraria lobota fibre biscuit of hypoglycemic defaecation |
KR102203094B1 (en) * | 2020-09-04 | 2021-01-14 | (주)자연미약선연구원 | Composition for preventing and improving menstrual pain and skin troubles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100795976B1 (en) * | 2006-06-13 | 2008-01-21 | 동아대학교 산학협력단 | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient |
KR100956278B1 (en) * | 2009-08-03 | 2010-05-10 | 대한약품공업 주식회사 | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus |
-
2012
- 2012-05-10 KR KR1020120049758A patent/KR101387695B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100795976B1 (en) * | 2006-06-13 | 2008-01-21 | 동아대학교 산학협력단 | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient |
KR100956278B1 (en) * | 2009-08-03 | 2010-05-10 | 대한약품공업 주식회사 | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104904942A (en) * | 2015-06-05 | 2015-09-16 | 王德富 | Blood glucose reducing tea and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20130126022A (en) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104322617B (en) | Biscuit of a kind of auxiliary hyperglycemic and preparation method thereof | |
CN104026446A (en) | Nutritional meal replacement powder suitable for crowd with hyperglycemia and preparation method thereof | |
KR101387695B1 (en) | The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus | |
CN102511712A (en) | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction | |
CN106975012A (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
CN104082672A (en) | Health-preserving porridge with efficacy of reducing blood sugar level and production method of porridge | |
CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
KR20110019569A (en) | Composition of health food | |
CN103355444A (en) | Health care tea paste for tonifying spleen and qi and preparation method | |
CN102125129B (en) | Health care tea | |
CN102125128A (en) | Nine-ingredient blood sugar reducing tea | |
CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
CN107751470A (en) | A kind of adlay fruity health tea cream and preparation method thereof | |
CN107737280A (en) | Chinese medicine composition for treating diabetes and its preparation method and application | |
CN105055851B (en) | A kind of Chinese medicine composition that treating diabetes, its preparation and its application | |
CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
CN111903803A (en) | Huangrong blood sugar reducing tea and preparation method thereof | |
CN103766453A (en) | Yam corn biscuit with health care effect on diabetes | |
Kamala et al. | Anti–Hyperglycemic and Anti–Hyperlipidemic Potentials of Psidium guajava Fruit Extract–a Review | |
CN103721074B (en) | Pharmaceutical composition and preparation method and application thereof | |
CN102000244B (en) | Traditional Chinese medicine preparation for treating diabetes mellitus | |
CN101757114A (en) | Hypoglycemic product and preparation method thereof | |
KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
CN104946491A (en) | Abalone-holothurian compound wine with blood sugar reducing function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180205 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 6 |